Regulus Therapeutics Inc. Company Profile

Background

Overview

Regulus Therapeutics Inc. is a clinical-stage biopharmaceutical company specializing in the development of innovative oligonucleotide therapeutics targeting microRNAs to treat a broad range of diseases. Established in 2007, the company focuses on genetically defined diseases, particularly orphan kidney diseases such as Autosomal Dominant Polycystic Kidney Disease (ADPKD). In June 2025, Regulus was acquired by Novartis AG, a global healthcare leader.

Mission and Vision

Regulus aims to develop important, novel oligonucleotide therapeutics designed to inhibit dysregulated microRNA targets for the benefit of patients with genetically based orphan diseases. The company's vision is to advance the understanding and treatment of diseases through the modulation of microRNA pathways, offering potential disease-modifying therapies.

Primary Area of Focus

The company's primary focus is on the development of microRNA-targeted therapies, with an initial emphasis on orphan kidney diseases, including ADPKD. By targeting specific microRNAs, Regulus aims to modulate gene expression and address underlying disease mechanisms.

Industry Significance

Regulus has been a pioneer in the field of microRNA therapeutics, contributing to the understanding and potential treatment of diseases through the modulation of microRNA pathways. The acquisition by Novartis underscores the strategic importance and potential of Regulus's therapeutic approaches in the biopharmaceutical industry.

Key Strategic Focus

Core Objectives

• Develop and commercialize oligonucleotide-based therapeutics targeting microRNAs to treat genetically defined diseases.

• Advance the clinical development of lead candidates, particularly in the area of orphan kidney diseases.

• Leverage strategic partnerships to enhance research capabilities and expedite product development.

Specific Areas of Specialization

• MicroRNA-targeted therapies

• Oligonucleotide-based drug development

• Orphan kidney diseases, with a focus on ADPKD

Key Technologies Utilized

• Antisense oligonucleotides

• MicroRNA inhibition

• Targeted drug delivery systems

Primary Markets or Conditions Targeted

• Orphan kidney diseases, especially ADPKD

• Other genetically defined diseases with unmet medical needs

Financials and Funding

Funding History

Regulus Therapeutics has successfully raised a total of $35 million across 11 funding rounds. The most recent funding activity was a Post-IPO round of $100 million completed in March 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities.

Notable Investors

• Alnylam Pharmaceuticals

• Novartis

• RA Capital

• Federated Hermes

• New Enterprise Associates

Intended Utilization of Capital

The capital raised has been utilized to advance the clinical development of lead candidates, particularly farabursen for ADPKD, support operational expenses, and enhance research and development capabilities. The acquisition by Novartis in June 2025 is expected to further accelerate the development and commercialization of Regulus's therapeutic candidates.

Pipeline Development

Key Pipeline Candidates

• Farabursen (RGLS8429): An investigational oligonucleotide drug targeting microRNA-17 (miR-17) for the treatment of ADPKD. Farabursen aims to modulate gene expression to slow or halt disease progression.

Stages of Clinical Trials or Product Development

• Phase 1b Multiple Ascending Dose Study: Completed in March 2025, this study evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of farabursen in adult patients with ADPKD. The study demonstrated a favorable safety profile and provided insights into the drug's potential efficacy.

Target Conditions

• Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Relevant Timelines for Anticipated Milestones

• Regulatory Approval: The acquisition by Novartis in June 2025 is expected to expedite the regulatory approval process for farabursen. Specific timelines for approval will depend on ongoing regulatory reviews.

Technological Platform and Innovation

Proprietary Technologies

• Antisense Oligonucleotides: Synthetic strands of nucleic acids designed to bind to specific mRNA molecules, modulating gene expression.

• MicroRNA Inhibition: Targeting specific microRNAs to regulate gene expression and address disease mechanisms.

Significant Scientific Methods

• Clinical Trials: Conducting rigorous clinical studies to evaluate the safety and efficacy of therapeutic candidates.

• Pharmacokinetic and Pharmacodynamic Studies: Assessing the absorption, distribution, metabolism, and excretion of drugs, as well as their biological effects.

Leadership Team

Jay Hagan – Chief Executive Officer

Jay Hagan has served as the CEO and principal executive officer of Regulus since May 2017. Under his leadership, the company advanced its clinical pipeline and strategic partnerships.

Cris Calsada – Chief Financial Officer

Cris joined Regulus in August 2019 as CFO. She has extensive experience in financial management within the life sciences sector, having previously served as CFO at Sanifit Therapeutics and held senior positions at Ambrx and Sony Online Entertainment.

Rekha Garg, M.D., M.S. – Chief Medical Officer

Dr. Garg joined Regulus in 2022, bringing over 20 years of experience in the biopharmaceutical industry. She has held leadership roles in clinical development, regulatory affairs, and risk management at companies such as Sanifit Therapeutics, Infinity Pharmaceuticals, Amgen, and Eli Lilly.

Christopher Aker – Senior Vice President & General Counsel

Christopher Aker serves as the Senior Vice President and General Counsel at Regulus, overseeing legal affairs and corporate governance.

Leadership Changes

In June 2025, Regulus Therapeutics was acquired by Novartis AG, leading to changes in the company's leadership structure. Specific details regarding leadership appointments post-acquisition are not publicly disclosed.

Competitor Profile

Market Insights and Dynamics

The market for microRNA-targeted therapeutics is emerging, with significant interest in developing treatments for genetically defined diseases. The ADPKD treatment market is valued at approximately $1.85 billion in 2025, currently dominated by one approved drug. Regulus's lead candidate, farabursen, represents a novel approach with potential for disease modification beyond the current standard of care.

Competitor Analysis

• Otsuka Pharmaceutical: Holds an estimated 80% market share in the ADPKD treatment market with its FDA-approved drug Tolvaptan (Jynarque).

• Alnylam Pharmaceuticals: A leader in RNA interference (RNAi) therapeutics, with a commercial-stage platform and multiple approved products.

Strategic Collaborations and Partnerships

The acquisition by Novartis in June 2025 is a significant strategic collaboration, providing Regulus with enhanced resources and expertise to advance its therapeutic candidates.

Operational Insights

Post-acquisition, Regulus operates as a subsidiary of Novartis, integrating into Novartis's global operations and leveraging its extensive resources to expedite the development and commercialization of its therapeutic candidates.

Strategic Opportunities and Future Directions

With the support of Novartis, Regulus is well-positioned to advance its pipeline, particularly farabursen for ADPKD, and explore additional applications of its microRNA-targeted therapies in other genetically defined diseases. The integration into Novartis's global network offers opportunities for expanded research, development, and market access.